Virtual Library
Start Your Search
J. Xu
Author of
-
+
P1.02 - Biology/Pathology (ID 614)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.02-057 - Analysis of C-MET Amplification Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion (ID 8282)
09:30 - 09:30 | Author(s): J. Xu
- Abstract
Background:
The MET receptor tyrosine kinase and its ligand, hepatocyte growth factor, is identified as a treatment target in lung cancer. c-MET gene abnormality can be distributed to various mechanisms including: overexpression, kinase activation, exon mutation, and amplification. c-MET gene amplification has been described as one of the reasons responsible for acquired EGFR tyrosine kinase inhibitor resistance. The aim of this study is to investigate the clinical value of c-MET gene amplification non-small cell lung cancer (NSCLC) blocks cell from pleural effusion.
Method:
Two hundred and fifeen cases of c-MET gene amplification non-small cell lung cancer (NSCLC) blocks cell from pleural effusion, Four hundred and four cases of tissues were detected by reverse transcription polymerase chain reaction (RT-PCR) method. The consistency of c-MET amplification was examined in 74 cases of patients with tissues and cell blocks.
Result:
c-MET amplification was found in 31 of 215 cell blocks (positive detection rate of 14.42%). c-MET amplification was detected in 35 of 404 tissue blocks (positive detection rate of 8.66%). There were 68cases in the 74 (91.89%) cases had the same consistency as tissue block. c-MET amplification was detected in 9 of 74 (12.16%) cell blocks, and 13 of 74 (17.57%) tissue blocks.
Conclusion:
The rate of c-MET amplification in cell blocks of NSCLC is higher than in matched tissue blocks. The patients with malignant pleural effusion are likely to tend c-MET amplification.
